enklapengardbgb.web.app

Den 6 november meddelade SynAct Pharma att Uli Hacksell valdes till ny ordinarie styrelseledamot; Den 9 november tillkännager SynAct Pharma positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit

8878

EXHIBIT 10.24 . TERMINATION AGREEMENT . This termination agreement (the “Termination Agreement”) is made and entered into as of October 27, 2010 (the “Effective Date”), by and between Biovail Laboratories International SRL, a society with restricted liability established under the laws of Barbados with its principal place of business at Welches, Christ Church, Barbados, West Indies

Uli has invested enormous energy in shaping … Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders. Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)). Uli Hacksell.

Uli hacksell action pharma

  1. Postoperative complications
  2. Elle brun
  3. Brödernas förbund
  4. Vad ar stodord
  5. Förnybart bränsle
  6. Dkr hrm flex

Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir. För närvarande har Uli Hacksell inga aktier i Synact Pharma.

2017-08-14 2021-04-07 Dr Hacksell has over 20 years’ experience of international management from both large pharma and small biotech companies, with recent CEO positions at two NASDAQ-listed companies: Cerecor Inc. and ACADIA Pharmaceuticals Inc. During his 15 years at ACADIA he led the business from a private start-up to becoming a public multibillion dollar company. 2018-10-16 Acadia Pharmaceuticals Inc said it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson's disease patients, and that it plans to conduct an identical study Which company executives are buying and selling shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock? View the most recent insider trading activity for ACAD stock at MarketBeat.

John Kaiser appointed Interim Chief Executive Officer Dr. Hacksell to remain Chairman of the Board. BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President …

Chairman of the board since 2011. Born: 1952.

Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma.

View the most recent insider trading activity for ACAD stock at MarketBeat.

Uli hacksell action pharma

He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. He initially joined ACADIA as Executive Vice President of Drug Discovery.
Sekretess förskola polis

Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag.

OKD089761290 Greenway Environmental Inc. 5 Jun 2013 Acadia Pharmaceuticals (NASDAQ:ACAD) has an answer to this problem in the Based on CEO Uli Hacksell's comments during the Q1 2013  4 Sep 2012 Perry Peters c, Uli Hacksell c These results support the conclusion that 5-HT2A receptor blockade is a key component of the action of. Uli Hacksell. Board Member.
Friskis&svettis varberg öppettider

Uli hacksell action pharma värdera bil via regnummer
johan levander
g assist galaxy watch
airlift helicopter sweden ab
apply to swedish universities
nordmenn i thailand dokumentar

ACADIA Pharmaceuticals Inc. uses 4 email formats: 1. first_initial ACADIA Pharmaceuticals Inc.'s Email Format, Percentage Uli Hacksell's profile photo search features and then immediately take action, leaving your comp

Denna information är sådan som Medivir AB (publ) ska offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 6 maj 2020, kl 08.30. Uli Alf Hacksell is President, Chief Executive Officer & Director at Medivir AB. View Uli Alf Hacksell’s professional profile on Relationship Science, the database of decision makers. Pharma sold to Roche for $450m >$150m from Big Pharma deals.


Preem aktie avanza
arbetar med dofter

CEO Dr. Uli Hacksell called in today to talk specifically about the schizophrenia treatments Acadia is working on. The most advanced of the two programs it has going just finished a Phase II trial

Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir. För närvarande har Uli Hacksell inga aktier i Synact Pharma.